A case of palmoplantar psoriasis successfully treated with apremilast

A 20-year-old woman had acquired a reddish plaque on her buttock since she was 3 years old. Subsequently, palmoplantar reddish plaque followed and she was diagnosed as having psoriasis bya dermatologist. She visited our department because her palmoplantar lesions graduallyworsened. Oral apremilast dramaticallyimproved her palmoplantar symptoms. Apremilast is a phosphodiesterase 4 inhibitor released in 2017 in Japan. Clinical trial of apremilast revealed that palmoplantar psoriasis physician global assessment score one or more became 0 in 46% of patients (placebo 25%). Palmoplantar psoriasis is often refractory by topical and/or ultravilolet therapy. As the first line of systemic therapy, apremilast can be a new option for this condition.